...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human vaccines & immunotherapeutics. >Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience
【24h】

Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience

机译：靶向肿瘤微环境，以改善基于自然杀伤细胞的免疫疗法：在正确的时间，正确的位置，有弹性的情况下

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Natural killer (NK) cell immunotherapies that target solid tumors require NK cells in the proper place, at the right time, with optimal function and a susceptible target cell. Basic research and clinical correlative studies have provided evidence, for certain malignancies, that intratumoral NK cells delay tumor progression. Whether NK cells exert anti-tumor effects for solid tumors is determined by a number of factors including homing and activating receptor expression by NK cells themselves and the sensitivity of tumor cells to be targets of NK cell cytolysis, which depends on the chemokine and NK cell-inhibitory and activating receptor ligand expression by tumor cells. Chemotherapeutic agents that increase NK cell-activating receptor ligands on tumor cells have been clinically promising as well as ectopic gene expression in NK cells with factors that overcome the suppressive mechanisms of the tumor microenvironment (TME). Identifying agents that decrease myeloid-derived suppressor cells (MDSC) or T regulatory (Treg) cell frequencies or function would be important to co-administer with adoptively transferred NK cells to ameliorate immunosuppressive TMEs. Thus, studies indicate that critical factors for NK cell immunotherapies targeting the TMEs are: being in the right place at the right time, with resilience.
机译：针对实体瘤的自然杀伤（NK）细胞免疫疗法需要在适当的时间，适当的位置，功能最佳的NK细胞和易受影响的靶细胞。基础研究和临床相关研究为某些恶性肿瘤提供了证据，即肿瘤内NK细胞会延迟肿瘤的进展。 NK细胞是否对实体瘤发挥抗肿瘤作用取决于许多因素，包括NK细胞自身的归巢和激活受体表达以及肿瘤细胞作为NK细胞溶细胞靶标的敏感性，这取决于趋化因子和NK细胞。 -肿瘤细胞的抑制和激活受体配体表达。具有克服肿瘤微环境（TME）的抑制机制的因素，增加肿瘤细胞上NK细胞活化受体配体的化学治疗剂以及NK细胞中异位基因表达在临床上是有前途的。降低骨髓源性抑制细胞（MDSC）或T调节（Treg）细胞频率或功能的鉴定试剂，对于与过继转移的NK细胞共同给药以改善免疫抑制性TME而言，将是重要的。因此，研究表明，针对TME的NK细胞免疫疗法的关键因素是：在正确的时间，正确的位置，具有复原力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号